But that is exactly what share prices of other ear
Post# of 36537
Here we are seeking excuses again, as to why it does not happen for GNBT.
Maybe not everybody has understood the PR, which I actually find much better written than the once written in recent history! It much better explains what they have achieved.
Maybe a lot of investors think "not another early stage vaccine manufacturer, we already have several approved. What the heck!"
I still think that they have made a much better job to explain why this vaccine is still needed.
What I actually think that they should've have put more emphazise on, is the therapeutic topic that mentioned only in a few short lines at the end.
Other than that, I am actually quiet happy with that PR. Jeannie is out of the bottle, now we just need to ask her to have the appropriate effect on the share price.